- Home
- SEED vs GTBP Comparison
SEED vs GTBP Comparison
Compare SEED & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEED | GTBP |
|---|---|---|
| Founded | 1997 | 1965 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 12.1M |
| IPO Year | 2005 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SEED | GTBP |
|---|---|---|
| Price | $1.25 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 60.6K | ★ 567.1K |
| Earning Date | 01-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $0.35 |
| 52 Week High | $2.49 | $3.73 |
Technical Indicators
Market Signals| Indicator | SEED | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 41.36 |
| Support Level | $0.97 | N/A |
| Resistance Level | $1.32 | $0.46 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 36.17 | 40.93 |
Price Performance
Historical ComparisonAbout SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company operating in the PRC including seed research and development activities featured in crop seed breeding and genetic improvement. The company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.